Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	1.00B
Revenue (ttm)	95.77M
Net Income (ttm)	-129.19M
Shares Out	38.03M
EPS (ttm)	-3.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,933
Open	26.21
Previous Close	26.11
Day's Range	25.95 - 26.63
52-Week Range	17.32 - 30.55
Beta	1.32
Analysts	Strong Buy
Price Target	53.75 (+104.14%)
Earnings Date	May 4, 2023

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM

Financial Performance

In 2022, MIRM's revenue was $77.06 million, an increase of 302.66% compared to the previous year's $19.14 million. Losses were -$135.67 million, 61.5% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $53.75, which is an increase of 104.14% from the latest price.

Price Target

$53.75

(104.14% upside)

Analyst Consensus: Strong Buy